The company has acquired stealthy Pipeline Medical Technologies.
As renal denervation procedures are making a comeback in treating resistant hypertension, Vascular Dynamics is going a different route to tackle the condition, by developing a stent-like application that will give therapy to patients.
With all of the indications Avinger is pursuing, it seems as if the Redwood City, CA-based company has an ‘infinite’ number of approaches in treating peripheral arterial disease patients.
The Mason, OH-based company said it has completed enrollment of the full cohort of 153 patients in the CONVERGE IDE clinical trial.
The Flagstaff, AZ-based company received the green light to market the Molding and Occlusion Balloon in the U.S., Japan, and Europe.
After favorable feasibility study results, Medtronic is beginning a pilot study of the Extravascular Implantable Cardioverter Defibrillator system.
Boston Scientific has had a tough time catching up to peers in the transcatheter aortic valve replacement (TAVR) market, but the company's latest news about the Lotus valve has been well received by investors.
Some of medtech’s largest companies are working for approval in the TMVR space, which could one day rival or surpass TAVR.
JenaValve has started an early feasibility study of the Pericardial TAVR technology for the minimally invasive treatment of patients with symptomatic, severe aortic stenosis, and symptomatic, severe aortic regurgitation.
United Therapeutics and Medtronic have received FDA approval for the SynchroMed II to deliver medication to treat pulmonary arterial hypertension.
Reva has received CE mark for the Motiv bioresorbable scaffold to be used for the treatment of below-the-knee peripheral artery disease.
Abbott acquired Tendyne back in 2015, a year where there was significant M&A activity in the transcatheter mitral valve replacement space.
CEO Mike Mahoney assured investors that Boston Scientific's seemingly aggressive M&A activity this year has all been part of a "very well-laid plan" and that the company still sees plenty of future tuck-in deals over the next 12 months.
The TAVR space is heavily dominated in the U.S. and Europe by Edwards Lifesciences and Medtronic, but Meril said there is enough room in the market for more players.